Disulfiram in Recurrent Glioblastoma

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

January 15, 2021

Study Completion Date

January 15, 2021

Conditions
GliomaGlioblastoma
Interventions
DRUG

Disulfiram

Disulfiram 400 mg daily

DIETARY_SUPPLEMENT

Copper

nutritional supplement with copper, 2 mg daily

DRUG

Alkylating Agents

Alkylating antineoplastic agent

Trial Locations (8)

Unknown

Cancer Clinic, St.Olavs University Hospital, Trondheim

Dept. of Oncology, Sahlgrenska University Hospital, Gothenburg

Ryhov County Hospital, Jönköping

Linköping University Hospital, Linköping

Lund University Hospital, Lund

Örebro University Hospital, Örebro

Karolinska University Hospital, Stockholm

Uppsala University Hospital, Uppsala

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

collaborator

Lund University Hospital

OTHER

collaborator

Karolinska University Hospital

OTHER

collaborator

University Hospital, Linkoeping

OTHER

collaborator

Region Örebro County

OTHER

collaborator

Ryhov County Hospital

OTHER

collaborator

Uppsala University Hospital

OTHER

lead

Sahlgrenska University Hospital

OTHER

NCT02678975 - Disulfiram in Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter